newsfilter
← Latest News
GlobeNewswire·

Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team